Results 151 to 160 of about 5,080 (193)

APOE-guided lecanemab dosing dissociates ARIA-E from ARIA-H: The K-ROAD study. [PDF]

Alzheimers Dement
Kang H, Jang H, Ahn J, Na DL, Lee JH, Kim EJ, Chun MY, Cho SH, Kim BC, Kim SE, Sohn G, Yun J, Lee JS, Park KC, Park HK, Kim YJ, Lee K, Yim S, Kim S, Kim JP, Kim HJ, Lim JS, Seo SW.   +22 more
europepmc   +1 more source

Longitudinal changes in DTI-ALPS and choroid plexus volume relative to CSF biomarkers during lecanemab treatment in mild cognitive impairment: A pilot study. [PDF]

Alzheimers Dement (Amst)
Takahashi T, Kimura K, Takenaka S, Ono S, Fukui M, Okada Y, Asada T, Niimi K, Ikeda A, Takahashi R, Matsumoto R, Fukuyama H.   +11 more
europepmc   +1 more source

Clarity AD open-label extension data do not robustly confirm disease course modification by lecanemab in ApoE₄ heterozygotes and non-carriers. [PDF]

J Prev Alzheimers Dis
Hazan J, Liu KY, Howard R.
europepmc   +1 more source

Demographic, Social, and Clinical Profiles of Patients Initiating Lecanemab in Clinical Practice: A Single-Center Experience in Korea. [PDF]

Dement Neurocogn Disord
Lee J, Kim H, Park HK, Kim S, Lee KB, Kang H, Shin D, Kim JP, Lee BH.   +8 more
europepmc   +1 more source

The Centiloid Scale in Amyloid PET Imaging: Current Role in Alzheimer's Disease Diagnosis, Treatment Planning, and Monitoring During Anti-Amyloid Therapy: A Clinical Perspective. [PDF]

Diagnostics (Basel)
Sotoudeh H, Alizadeh M.
europepmc   +1 more source

Quantitative Medicine to Support Drug Development and Regulatory Decisions: A UK Regulatory Approach Informed by ICH M15. [PDF]

Clin Transl Sci
Kerwash E, Butler AS, Malamatari M, Cole S.   +3 more
europepmc   +1 more source

Pre- and Post-synapses Contain Lecanemab-reactive Amyloid-β in Post-mortem Human Alzheimer’s Disease Brain

Holt K, Chang YY, Li M, Albertini G, Smith C, Tulloch J, De Strooper B, Hardingham GE, Spires-Jones TL.   +8 more
europepmc   +1 more source

Lecanemab in Early Alzheimer’s Disease [PDF]

New England Journal of Medicine, 2023
The accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may initiate or potentiate pathologic processes in Alzheimer's disease. Lecanemab, a humanized IgG1 monoclonal antibody that binds with high affinity to Aβ soluble protofibrils, is being tested in persons with early Alzheimer's disease.We conducted an 18-month, multicenter, double ...
van Dyck, Christopher, Swanson, Chad, Aisen, Paul, Bateman, Randall, Chen, Christopher, Gee, Michelle, Kanekiyo, Michio, Li, David, Reyderman, Larisa, Cohen, Sharon, Froelich, Lutz, Katayama, Sadao, Sabbagh, Marwan, Vellas, Bruno, Watson, David, Dhadda, Shobha, Irizarry, Michael, Kramer, Lynn, Iwatsubo, Takeshi   +18 more
core   +11 more sources

Lecanemab: First Approval

Drugs, 2023
Lecanemab (lecanemab-irmb; LEQEMBI™) is a humanized immunoglobulin gamma 1 (IgG1) against aggregated soluble and insoluble forms of amyloid-β peptide. It is being developed by Eisai, under a global licence from BioArctic (formerly BioArctic Neuroscience), and in collaboration with Biogen, for the treatment of Alzheimer's disease, and received its first
Sheridan M. Hoy (4897468)
openaire   +3 more sources

Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics

journal of prevention of Alzheimer's disease, The
International audienceLecanemab, a monoclonal antibody targeting β-amyloid protofibrils, has shown promising results in a Phase III clinical trial for the treatment of early stages of Alzheimer's disease (AD) and has been approved by the European ...
Matthieu Lilamand, Charlotte Cordonnier, Nicolas Villain   +2 more
exaly   +2 more sources